Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study.
Cardiac amyloidosis
Disease stage
NAC score
Prognostic scoring
Wild‐type transthyretin cardiac amyloidosis
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
20 Sep 2024
20 Sep 2024
Historique:
revised:
27
08
2024
received:
04
08
2024
accepted:
06
09
2024
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
20
9
2024
Statut:
aheadofprint
Résumé
Disease staging and prognostic scoring in wild-type transthyretin-related cardiac amyloidosis (ATTRwt-CA) can be captured by two systems (NAC and Columbia scores). However, uncertainty remains as epidemiology of the disease is evolving rapidly. We evaluated features associated with staging systems across ATTRwt-CA patients from different diagnostic pathways, and their association with prognosis. We performed an analysis on DIAMOND patients with available data to evaluate NAC and Columbia score. DIAMOND was a retrospective study from 17 Italian referral centres for CA, enrolling 1281 patients diagnosed between 2016 and 2021, and aimed at describing characteristics of pathways leading to ATTRwt-CA diagnosis. Of the original cohort, 811 patients were included in this analysis. Each patient had NAC and Columbia score calculated. Patients were grouped according to NAC and Columbia scoring classes. We described characteristics of patients according to staging classes and diagnostic pathways at diagnosis. Prevalence of early diagnoses, defined as NAC Ia, NYHA class I, no use of diuretics, no history of heart failure (HF) hospitalizations nor of atrial fibrillation prior to diagnosis, was investigated. Finally, prognostic variables were tested alone and grouped as NAC or Columbia scores in Cox univariate and multivariate regression analyses. Prognosis was investigated as all-cause mortality, in the whole population and dividing patients in HF versus other diagnostic pathways. Only 1% of the study population had an early ATTRwt-CA diagnosis. Distribution of prognostic variables and of NAC and Columbia classes was heterogeneous across diagnostic pathways. The prevalence of NAC III and Columbia III was higher in the HF diagnostic pathway, but all NAC and Columbia classes were present in all pathways. Both NAC and Columbia scores were associated with all-cause mortality at univariate Cox regression analysis in the whole population, in patients from the HF diagnostic pathway and in those from other pathways. At multivariate analysis, Columbia score remained significantly associated with the outcome, together with age at diagnosis, left ventricular ejection fraction and maximal wall thickness. In this contemporary nationwide cohort, an ATTRwt-CA early diagnosis was very rare. Disease staging with NAC and Columbia scoring systems determined classes of patients with heterogeneous features. Both scores were significantly associated with mortality, but other variables also had prognostic significance.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Pfizer
ID : 64890405
Informations de copyright
© 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington‐Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007‐1016. doi:10.1056/NEJMoa1805689
Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia‐Pavia P, Gibbs S, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 2024;390:132‐142. doi:10.1056/NEJMoa2305434
Coelho T, Dispenzieri A, Grogan M, Conceição I, Waddington‐Cruz M, Kristen AV, et al. Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay. Amyloid 2023;30:445‐448. doi:10.1080/13506129.2023.2229484
Tini G, Milani P, Zampieri M, Caponetti AG, Fabris F, Foli A, et al. Diagnostic pathways to wild‐type transthyretin amyloid cardiomyopathy: a multicentre network study. Eur J Heart Fail 2023;25:845‐853. doi:10.1002/ejhf.2823
Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez‐Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018;39:2799‐2806. doi:10.1093/eurheartj/ehx589
Cheng RK, Levy WC, Vasbinder A, Teruya S, De Los Santos J, Leedy D, et al. Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis. JACC: CardioOncology 2020;2:414‐424. doi:10.1016/j.jaccao.2020.06.007
Law S, Bezard M, Petrie A, Chacko L, Cohen OC, Ravichandran S, et al. Characteristics and natural history of early‐stage cardiac transthyretin amyloidosis. Eur Heart J 2022;43:2622‐2632. doi:10.1093/eurheartj/ehac259
Zampieri M, Nardi G, Del Monaco G, Allinovi M, Gabriele M, Zocchi C, et al. Changes in the perceived epidemiology of amyloidosis: 20 year‐experience from a tertiary referral Centre in Tuscany. Int J Cardiol 2021;335:123‐127. doi:10.1016/j.ijcard.2021.04.023
Ioannou A, Patel RK, Razvi Y, Porcari A, Sinagra G, Venneri L, et al. Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation 2022;146:1657‐1670. doi:10.1161/CIRCULATIONAHA.122.060852
Aimo A, Tomasoni D, Porcari A, Vergaro G, Castiglione V, Passino C, et al. Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis. Eur J Heart Fail 2023;25:510‐514. doi:10.1002/ejhf.2824
Cipriani A, De Michieli L, Porcari A, Licchelli L, Sinigiani G, Tini G, et al. Low QRS voltages in cardiac amyloidosis: clinical correlates and prognostic value. JACC CardioOncol 2022;4:458‐470. doi:10.1016/j.jaccao.2022.08.007
Fumagalli C, Zampieri M, Perfetto F, Zocchi C, Maurizi N, Tassetti L, et al. Early diagnosis and outcome in patients with wild‐type transthyretin cardiac amyloidosis. Mayo Clin Proc 2021;96:2185‐2191. doi:10.1016/j.mayocp.2021.04.021
Rørth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS, et al. Comparison of BNP and NT‐proBNP in patients with heart failure and reduced ejection fraction. Circ Heart Fail 2020;13:e006541. doi:10.1161/CIRCHEARTFAILURE.119.006541
Ameri P, Canepa M, Fabbi P, Leoncini G, Milaneschi Y, Mussap M, et al. Vitamin D modulates the association of circulating insulin‐like growth factor‐1 with carotid artery intima‐media thickness. Atherosclerosis 2014;236:418‐425. doi:10.1016/j.atherosclerosis.2014.08.022
Rohde LE, Zimerman A, Vaduganathan M, Claggett BL, Packer M, Desai AS, et al. Associations between New York Heart Association classification, objective measures, and long‐term prognosis in mild heart failure: a secondary analysis of the PARADIGM‐HF trial. JAMA Cardiol 2023;8:150‐158. doi:10.1001/jamacardio.2022.4427
Westin O, Fosbøl EL, Maurer MS, Leicht BP, Hasbak P, Mylin AK, et al. Screening for cardiac amyloidosis 5 to 15 years after surgery for bilateral carpal tunnel syndrome. J Am Coll Cardiol 2022;80:967‐977. doi:10.1016/j.jacc.2022.06.026
Vianello PF, La Malfa G, Tini G, Mazzola V, Miceli A, Santolini E, et al. Prevalence of transthyretin amyloid cardiomyopathy in male patients who underwent bilateral carpal tunnel surgery: the ACTUAL study. Int J Cardiol 2020;329:144‐147. doi:10.1016/j.ijcard.2020.12.044
AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol 2021;6:1267‐1274. doi:10.1001/jamacardio.2021.3070
Yamasaki H, Kondo H, Shiroo T, Iwata N, Masuda T, Makita T, et al. Efficacy of computed tomography‐based evaluation of myocardial extracellular volume combined with red flags for early screening of concealed cardiac amyloidosis in patients with atrial fibrillation. Circ J 2024;88:1167‐1175. doi:10.1253/circj.CJ‐23‐0948
Merlo M, Pagura L, Porcari A, Cameli M, Vergaro G, Musumeci B, et al. Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from phase 2 of the AC‐TIVE study, an Italian nationwide survey. Eur J Heart Fail 2022;24:1377‐1386. doi:10.1002/ejhf.2504
Cannie D, Patel K, Protonotarios A, Heenan I, Bakalakos A, Syrris P, et al. Prevalence of transthyretin cardiac amyloidosis in patients with high‐degree AV block. Open Heart 2024;11:e002606. doi:10.1136/openhrt‐2024‐002606
Rapezzi C, Giannini F, Campo G. Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle? Eur J Heart Fail 2021;23:259‐263. doi:10.1002/ejhf.2057
Tini G, Sessarego E, Benenati S, Vianello PF, Musumeci B, Autore C, et al. Yield of bone scintigraphy screening for transthyretin‐related cardiac amyloidosis in different conditions: methodological issues and clinical implications. Eur J Clin Invest 2021;51:e13665. doi:10.1111/eci.13665
Castiglione V, Aimo A, Vergaro G. Cost‐effectiveness of transthyretin cardiac amyloidosis screening and treatment: a dilemma for the clinician. Int J Cardiol 2024;402:131855. doi:10.1016/j.ijcard.2024.131855
Law S, Petrie A, Chacko L, Cohen OC, Ravichandran S, Gilbertson JA, et al. Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Failure 2020;7:3942‐3949. doi:10.1002/ehf2.12989
Ioannou A, Nitsche C, Porcari A, Patel RK, Razvi Y, Rauf MU, et al. Multiorgan dysfunction and associated prognosis in transthyretin cardiac amyloidosis. J Am Heart Assoc 2024;13:e033094. doi:10.1161/JAHA.123.033094
Chan N, Teruya S, Mirabal A, Weinsaft AY, Santos JDL, Guadalupe S, et al. Temporal outcomes of patients diagnosed with transthyretin cardiac amyloidosis. J Card Fail 2024;S1071‐9164:00073‐00073. doi:10.1016/j.cardfail.2024.02.014